Preclinical Director since 2021
Christina Kalderén has a PhD in Medical Sciences from Karolinska Institute and a Master degree in Biotechnology and Bioengineering from KTH. She has more than 25 years´ experience of R&D in pharmaceutical industry as project leader, section head and senior researcher. Christina started her career at KabiGen, later Kabi Pharmacia as researcher and section head where she built up the section for prokaryotic process development of biologics such as growth hormones and therapeutic antibodies. In 2001 she joined Biovitrum, later SOBI where she focused on drug discovery of small molecules and biologics in therapeutic fields of inflammation and fibrosis. Since 2013, she has been a member of the Helleday Laboratory, Karolinska institutet. In this position she has led and developed the OGG1 project to preclinical development phase. Christina started at Oxcia in June 2021 as preclinical director.
Holdings : 0 A-shares, 26 250 B-shares and 27 000 warrants.